Psychiatric and Behavioral Symptoms in Alzheimer s and Other Dementias. Aaron H. Kaufman, MD

Size: px
Start display at page:

Download "Psychiatric and Behavioral Symptoms in Alzheimer s and Other Dementias. Aaron H. Kaufman, MD"

Transcription

1 Psychiatric and Behavioral Symptoms in Alzheimer s and Other Dementias Aaron H. Kaufman, MD

2 Psychiatric and Behavioral Symptoms in Alzheimer s and Other Dementias Aaron H. Kaufman, M.D. Health Sciences Associate Clinical Professor Department of Psychiatry and Biobehavioral Sciences Geffen School of Medicine at UCLA September 10, 2016

3 Disclosures Research and Academic Support Industry Grant: ANS/St. Jude Medical - Deep Brain Stimulation for Treatment Resistant Depression (Sub-Investigator) collaboration with R. Espinoza, Principal Investigator Off-label use of medications for treatment will be discussed

4 Objectives At the end of this session, participants will be able to: Describe the most common psychiatric and behavioral symptoms encountered in individuals with dementia Consider some of the pharmacologic and nonpharmacologic options in the management of psychiatric and behavioral symptoms in individuals with dementia List some of the concerns with using antipsychotics for the management of behavioral symptoms

5 Case #1 Mr. J is an 84 year old gentleman with a 5 year history of cognitive impairment. His instrumental activities of daily living have been steadily declining He now requires a caregiver at home for assistance. He has lost motivation to participate in previous interests. He frequently wakes in the middle of the night.

6 Case #1 When Mr. J does awaken at night, he believes that his home is not his real home. He makes attempts to leave his residence in the middle of the night. On one occasion he thought he saw someone stealing from his home and he grabbed a kitchen knife for protection.

7 Older Americans 65+ years = 40.3 million in 2010 Represents 13.0% of the U.S. population, about one in every eight Americans By 2030, there will be about 71.5 million older persons, more than twice their number in 2000 People 65+ represented 12.4% of the population in the year 2000 but are expected to grow to be 20% of the population by 2030 Department of Health and Human Services - Administration on Aging

8 Alzheimer s Disease Affects 1 in 8 older adults 5.4 million Americans have AD Rates increase with age

9 Characterized by Dementia Decline in Cognition Decline in Activities of Daily Living Behavioral and Psychiatric Symptoms Hersch EC & Falzgraf S. Clinical Interventions in Aging 2007 De Dyn 2005

10 Behavioral and Psychiatric Symptoms in Dementia (BPSD) Agitation Aggressive Physical Aggression Vocalizing/Shouting Verbal Insults Non-Aggressive Pacing Restlessness Wandering Purposeless motor behavior Psychosis Delusions Hallucinations Mood/Anxiety/Sleep Depression Euphoria Apathy Irritability Sleep disturbance Appetite/eating Obsessive ruminations Personality Changes Disinhibition Withdrawal Hypersexuality

11 Why are BPSD Important? Distressing for patient Distressing for family and caregivers Caregiver burnout Caregiver depression Reduced quality of life Increase in risk for institutionalization Ballard CG, et al. Curr Opin Psychiatry 2009 Gilley DW 1991, Rabins PV 1982 Ballard CG 2001, Banerjee S 2006 Steele C 1990

12 How Common are BPSD? At least 80-90% experience at least 1 symptom during the course of dementia Agitation/Aggression 20% of patients with AD in clinical settings 40-60% of patients in Long Term Care Psychosis 25% of patients in clinical settings Depression 20% of patients in clinical settings Ballard CG, et al. Curr Opin Psychiatry 2009 Steinberg M 2008, Aalten P 2003 Lyketsos CG 2000, Margallo-Lana M 2001 Burns A 1990

13 Cache County Study of Memory in Aging Study of elderly residents of Cache County, Utah Over 5000 screened for cognitive impairment Evaluated prevalence of behavioral symptoms in the elderly 329 with dementia compared to 673 without dementia Lyketsos CG, et al. Am J Psychiatry 2000

14 30 25 Cache County X-Axis NPI Item 1 Apathy 2 Depression 3 Agitation 4 Irritability 5 Delusions 6 Anxiety 7 Motor 8 Hallucinations 9 Disinhibition 10 Elation Dementia No Dementia Lyketsos CG, et al. Am J Psychiatry 2000

15 Assessment of BPSD New Symptom Delirium Pain Sensory Deficit Dementia

16 Non-pharmacologic Treatment Aromatherapy 4 RCTs (< 4-12 weeks) 2 with Lavender oil 2 with Melissa oil Safe +/- efficacy Bright Light Therapy 3 controlled trials for sleep disturbance and restlessness Some benefit for restlessness Safe Ballard CG, et al. International Review of Psychiatry 2008 Burns A 2002, Ballard CG 2002, Burns A, et al. Dement Geriatr Cogn Disord 2011

17 Non-pharmacologic Treatment Reminiscence Personalized music Structured social activities Person centered bathing Pet therapy Others

18 Pharmacologic Treatment of Aggression & Agitation 1st Generation Antipsychotics Several trials for BPSD Best studied is Haloperidol Length of trials 4-12 weeks (+) Aggression (+/-) Psychosis (-) Non-aggressive agitation Side effects include acute dystonias, extrapyramidal side effects, tardive dyskinesia Ballard CG and Corbett A. CNS Drugs 2010 Lonergan E 2005.

19 Pharmacologic Treatment of Aggression & Agitation 2nd Generation Antipsychotics Several trials for BPSD Length of trials 6-12 weeks Side effects include weight gain, dyslipidemia, sedation, orthostatic hypotension and others Ballard CG and Corbett A. CNS Drugs 2010

20 Pharmacologic Treatment of Aggression & Agitation 2nd Generation Antipsychotics Risperidone (+) Aggression at 2 mg/day (+) Psychosis at 1 mg/day (-) Non-aggressive agitation Aripiprazole (+) Aggression (+) Psychosis at 10 mg/day Quetiapine (-) Agitation Olanzapine (+/-) Agitation/aggression/psychosis at 5-10 mg/day Ballard CG and Corbett A. CNS Drugs 2010

21 Pharmacologic Treatment of Aggression & Agitation Clinical Antipsychotic Trials of Intervention Effectiveness Study (CATIE-AD) Compared Risperidone, Olanzapine, Quetiapine and Placebo Primary Phase 1 Outcome: Time until discontinuation of agents For discontinuation due to lack of efficacy Risperidone 26.7 weeks, mean last prescribed dose 1 mg/day Olanzapine 22.1 weeks, mean last prescribed dose 5.5 mg/day Quetiapine 9.1 weeks, mean last prescribed dose 56.5 mg/day Placebo 9.0 weeks Discontinuations due to intolerability Risperidone 18% Olanzapine 24% Quetiapine 16% Placebo 5% Sultzer DL, et al. Am J Psychiatry Schneider LS, et al. N Engl J Med 2006.

22 Pharmacologic Treatment of Aggression & Agitation Antipsychotics carry risk! Mortality risk Cardiovascular risk Decreased cognition Falls Edema Pneumonia Ballard CG and Corbett A. CNS Drugs 2010 FDA Schneider LS Wang PS Ballard C 2009 McShane R Ballard C 2005 Schneider LS Ballard C 2006

23 Pharmacologic Treatment of Aggression & Agitation Cholinesterase Inhibitors Small effect overall No acute benefit Possibly helpful for psychosis in DLB Memantine Some benefit possibly over 3-6 months in AD Unclear role thus far Antidepressants Citalopram 17 day trial in acute inpatients showed benefit Trazodone Studies suggest benefit, but double blind trial negative Anticonvulsants Carbamazepine 2 small studies were positive Valproate Disappointing results Oxcarbazepine Single study with trend toward improvement Gabapentin Minimal data Benzodiazepines Possibly helpful, but risks of sedation, falls, worsening cognition, disinhibition Alpha-blockers Prazosin Small 8-week trial showing benefit Ballard CG, et al. Curr Opin Psychiatry 2009 Corbett A, et al. Curr Treat Options Neurol 2012

24 Pharmacologic Treatment of Depression Antidepressants SSRIs (+/-) Sertraline (-) Fluoxetine TCAs (+) Clomipramine (-) Imipramine SNRIs No data Other - (-) Mirtazapine No trials for Vascular Dementia No trials for Dementia with Lewy Bodies Ballard CG, et al. Curr Opin Psychiatry 2009 Bains J Petracca G Reifler BV 1989 Petracca GM Lyketsos CG 2003 Banerjee S, et al. Lancet 2011.

25 Pharmacologic Considerations Citalopram/Sertraline Depression, irritability, anxiety and sleep disturbance. Trazodone Sleep disturbance, agitation Benzodiazepines Anxiety, agitation, but beware falls, sedation, worsening cognition, disinhibition Risperidone/Olanzapine/Aripiprazole Aggression, agitation and psychosis, but only for severe symptoms and ideally for short term only Cholinesterase Inhibitors Consider if not already added for AD +/- memantine

26 Principles of Treatment Non-Pharmacologic treatments are 1 st line Many symptoms have remissions or fluctuate and may improve over several weeks If pharmacologic interventions pursued: Start with least harmful and progress If treatment carries risk, discuss with patient/family Make attempts at withdrawing therapy, if possible

27 Recommended Reading Ballard C and Corbett A. Management of neuropsychiatric symptoms in people with dementia. CNS Drugs 2010; 24 (9): Ballard C, et al. Management of agitation and aggression associated with Alzheimer s disease: controversies and possible solutions. Current Opinion in Psychiatry 2009; 22: Corbett A, et al. Treatment of behavioral and psychological symptoms of Alzheimer s disease. Current Treatment Options in Neurology 2012; 14: Reus VI, et al. The American Psychiatric Association Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients with Dementia. The American Journal of Psychiatry 2016; 173(5):543-6.

28 Questions? Aaron H. Kaufman, M.D. Health Sciences Associate Clinical Professor Department of Psychiatry and Biobehavioral Sciences Semel Institute of Neuroscience and Human Behavior David Geffen School of Medicine at UCLA

Management of the Acutely Agitated Long Term Care Patient

Management of the Acutely Agitated Long Term Care Patient Management of the Acutely Agitated Long Term Care Patient 80 60 Graying of the Population US Population Over Age 65 Millions of Persons 40 20 0 1900 1920 1940 1960 1980 1990 2010 2030 Year Defining Dementia

More information

BEHAVIOURAL AND PSYCHOLOGICAL SYMPTOMS IN DEMENTIA

BEHAVIOURAL AND PSYCHOLOGICAL SYMPTOMS IN DEMENTIA BEHAVIOURAL AND PSYCHOLOGICAL SYMPTOMS IN DEMENTIA Unmet needs What might be your behavioural response to this experience? Content Definition What are BPSD? Prevalence How common are they? Aetiological

More information

Optimal Management of Challenging Behaviours in Dementia: An Update on Pharmacologic and Non-Pharmacologic Approaches

Optimal Management of Challenging Behaviours in Dementia: An Update on Pharmacologic and Non-Pharmacologic Approaches Optimal Management of Challenging Behaviours in Dementia: An Update on Pharmacologic and Non-Pharmacologic Approaches Andrea Iaboni, MD, DPhil, FRCPC Toronto Rehab Institute, UHN Learning objectives Recognize

More information

11/11/2016. Disclosures. Natural history of BPSD. Objectives. Assessment of BPSD. Behavioral Management of Persons with Alzheimer s Disease

11/11/2016. Disclosures. Natural history of BPSD. Objectives. Assessment of BPSD. Behavioral Management of Persons with Alzheimer s Disease Disclosures Behavioral Management of Persons with Alzheimer s Disease Wisconsin Association of Medical Directors November 17, 2016 Art Walaszek, M.D. Professor of Psychiatry UW School of Medicine & Public

More information

NeuroPharmac Journal ISSN: Alzheimer s Disease: Pharmacotherapy of noncognitive symptoms Aslam Pathan; Abdulrahman M.

NeuroPharmac Journal ISSN: Alzheimer s Disease: Pharmacotherapy of noncognitive symptoms Aslam Pathan; Abdulrahman M. ISSNISSN ISSN: 2456-3927 NeuroPharmac Journal Alzheimer s Disease: Pharmacotherapy of noncognitive symptoms Aslam Pathan; Abdulrahman M. Alshahrani www. neuropharmac.com Jan-April 2018, Volume 3, Issue

More information

USING ANTIPSYCHOTICS TO TREAT THE BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS OF DEMENTIA (BPSD)- WHAT IS THE EVIDENCE?

USING ANTIPSYCHOTICS TO TREAT THE BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS OF DEMENTIA (BPSD)- WHAT IS THE EVIDENCE? USING ANTIPSYCHOTICS TO TREAT THE BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS OF DEMENTIA (BPSD)- WHAT IS THE EVIDENCE? Mugdha Thakur, MD Associate Professor of Psychiatry and Behavioral Sciences Duke University

More information

Pharmacological Treatment of Aggression in the Elderly

Pharmacological Treatment of Aggression in the Elderly Pharmacological Treatment of Aggression in the Elderly Howard Fenn, MD Adjunct Clinical Associate Professor Department of Psychiatry and Behavioral Sciences Stanford University Self-Assessment Question

More information

Treatment of behavioral and psychological symptoms of dementia: a systematic review

Treatment of behavioral and psychological symptoms of dementia: a systematic review Psychiatr. Pol. 2016; 50(4): 679 715 PL ISSN 0033-2674 (PRINT), ISSN 2391-5854 (ONLINE) www.psychiatriapolska.pl DOI: http://dx.doi.org/10.12740/pp/64477 Treatment of behavioral and psychological symptoms

More information

Management of Agitation in Dementia. Kimberly Triplett Ferguson, MS4

Management of Agitation in Dementia. Kimberly Triplett Ferguson, MS4 Management of Agitation in Dementia Kimberly Triplett Ferguson, MS4 Objectives 1. Review recommended evaluation of agitated patients with dementia. 2. Discuss evidence concerning nonpharmacologic management.

More information

Psychosis and Agitation in Dementia

Psychosis and Agitation in Dementia Psychosis and Agitation in Dementia Dilip V. Jeste, MD Estelle & Edgar Levi Chair in Aging, Director, Stein Institute for Research on Aging, Distinguished Professor of Psychiatry & Neurosciences, University

More information

DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017.

DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017. DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017. Introduction. Parkinson's disease (PD) has been considered largely as a motor disorder. It has been increasingly recognized that

More information

Antipsychotic Medications

Antipsychotic Medications TRAIL: Team Review of EVIDENCE REVIEW & RECOMMENDATIONS FOR LTC Behavioural and psychological symptoms of dementia (BPSD) refer to the non-cognitive symptoms of disturbed perception, thought content, mood

More information

BEHAVIORAL PROBLEMS IN DEMENTIA

BEHAVIORAL PROBLEMS IN DEMENTIA BEHAVIORAL PROBLEMS IN DEMENTIA CLINICAL FEATURES Particularly as dementia progresses, psychiatric symptoms may develop that resemble discrete mental disorders such as depression or mania The course and

More information

ANTIPSYCHOTICS IN LONG TERM CARE: Are We Doing More Harm than Good?

ANTIPSYCHOTICS IN LONG TERM CARE: Are We Doing More Harm than Good? ANTIPSYCHOTICS IN LONG TERM CARE: Are We Doing More Harm than Good? STEPHANIE M. OZALAS, PHARMD, BCPS, BCGP VA MARYLAND HEALTH CARE SYSTEM BALTIMORE, MD DISCLOSURES Off-label use of medications will be

More information

MANAGEMENT OF NEUROPSYCHIATRIC SYMPTOMS OF DEMENTIA

MANAGEMENT OF NEUROPSYCHIATRIC SYMPTOMS OF DEMENTIA MANAGEMENT OF NEUROPSYCHIATRIC SYMPTOMS OF DEMENTIA Dr. Dallas Seitz MD PhD FRCPC Associate Professor and Division Chair, Division of Geriatric Psychiatry Department of Psychiatry, Queen s University President,

More information

Behavioral and Psychological Symptoms of dementia (BPSD)

Behavioral and Psychological Symptoms of dementia (BPSD) Behavioral and Psychological Symptoms of dementia (BPSD) Chris Collins - Old Age Psychiatrist, Christchurch chris.collins@cdhb.health.nz Approaching BPSD: the right mindset Assessment Non-drug management

More information

Behavioral Issues in Dementia. March 27, 2014 Dylan Wint, M.D.

Behavioral Issues in Dementia. March 27, 2014 Dylan Wint, M.D. Behavioral Issues in Dementia March 27, 2014 Dylan Wint, M.D. OVERVIEW Key points Depression Definitions and detection Treatment Psychosis Definitions and detection Treatment Agitation SOME KEY POINTS

More information

MEDICATIONS IN MANAGING DIFFICULT BEHAVIORS

MEDICATIONS IN MANAGING DIFFICULT BEHAVIORS MEDICATIONS IN MANAGING DIFFICULT BEHAVIORS A REALITY CHECK reality check Noun informal an occasion on which one is reminded of the state of things in the real world. ROBERT LACOSTE, MD MEDICAL DIRECTOR,

More information

Lewy Body Disease. Dementia Education for the First Responder July 27, 2017

Lewy Body Disease. Dementia Education for the First Responder July 27, 2017 Lewy Body Disease Dementia Education for the First Responder July 27, 2017 Dylan Wint, M.D. NV Energy Chair for Brain Health Education Cleveland Clinic Lou Ruvo Center for Brain Health OUTLINE Lewy body

More information

Clinical Trial Designs for RCTs focussing on the Treatment of Agitation in people with Alzheimer s disease

Clinical Trial Designs for RCTs focussing on the Treatment of Agitation in people with Alzheimer s disease Clinical Trial Designs for RCTs focussing on the Treatment of Agitation in people with Alzheimer s disease Professor Clive Ballard Dr Byron Creese University of Exeter, UK Guardian guide for 2018: Top

More information

Management of Behavioral Problems in Dementia

Management of Behavioral Problems in Dementia Management of Behavioral Problems in Dementia Ghulam M. Surti, MD Clinical Assistant Professor Department of Psychiatry and Human Behavior Warren Alpert Medical School of Brown University Definition of

More information

Pharmacological Treatment of Behavioural and Psychological Symptoms of Dementia (BPSD) Gurdeep K Major St. Charles Hospital

Pharmacological Treatment of Behavioural and Psychological Symptoms of Dementia (BPSD) Gurdeep K Major St. Charles Hospital Pharmacological Treatment of Behavioural and Psychological Symptoms of Dementia (BPSD) Gurdeep K Major St. Charles Hospital with thanks to Jonathan Cavan for his input Aims Define BPSD and common symptoms

More information

Pharmacological Treatments for Neuropsychiatric Symptoms in Dementia 3/22/2018

Pharmacological Treatments for Neuropsychiatric Symptoms in Dementia 3/22/2018 Pharmacological Treatments for Neuropsychiatric Symptoms in Dementia 3/22/2018 Mary Ellen Quiceno, MD, FAAN Associate Professor of Neurology UNTHSC Center for Geriatrics 855 Montgomery Street, PCC 4, Ft.

More information

Guidelines for the Management of Behavioural and Psychological Symptoms of Dementia (BPSD) Summary document for Primary Care

Guidelines for the Management of Behavioural and Psychological Symptoms of Dementia (BPSD) Summary document for Primary Care Guidelines for the Management of Behavioural and Psychological Symptoms of Dementia (BPSD) Summary document for Primary Care Guidelines for the Management of Behavioural and Psychological Symptoms of Dementia

More information

Medication alternatives for behavioural disturbance

Medication alternatives for behavioural disturbance Neurology 13 Medication alternatives for behavioural disturbance Many patients with dementia will in the later stages develop distressing behavioural symptoms. Antipsychotics are commonly used to treat

More information

Disclosure. Speaker Bureaus. Grant Support. Pfizer Forest Norvartis. Pan American Health Organization/WHO NIA HRSA

Disclosure. Speaker Bureaus. Grant Support. Pfizer Forest Norvartis. Pan American Health Organization/WHO NIA HRSA Disclosure Speaker Bureaus Pfizer Forest Norvartis Grant Support Pan American Health Organization/WHO NIA HRSA How Common is Psychosis in Alzheimer s Disease? Review of 55 studies 41% of those with Alzheimer

More information

Recognition and Management of Behavioral Disturbances in Dementia

Recognition and Management of Behavioral Disturbances in Dementia Recognition and Management of Behavioral Disturbances in Dementia Danielle Hansen, DO, MS (Med Ed), MHSA INTRODUCTION 80% 90% of patients with dementia develop at least one behavioral disturbances or psychotic

More information

How I Treat Aggression in Outpatients With Dementia. C. Omelan MD, FRCP(C)

How I Treat Aggression in Outpatients With Dementia. C. Omelan MD, FRCP(C) How I Treat Aggression in Outpatients With Dementia C. Omelan MD, FRCP(C) Conflict of Interest I have no potential conflicts of interest to declare Overview Outline the prevalence of aggression Review

More information

Assessment and management of behavioral and psychological symptoms of dementia

Assessment and management of behavioral and psychological symptoms of dementia Assessment and management of behavioral and psychological symptoms of dementia Helen C Kales, 1 2 3 Laura N Gitlin, 4 5 6 Constantine G Lyketsos 7 1 Section of Geriatric Psychiatry, Department of Psychiatry,

More information

Organization: Sheppard Pratt Health System Solution Title: Lean Methodology: Appropriate Antipsychotic Use on an Inpatient Dementia Unit

Organization: Sheppard Pratt Health System Solution Title: Lean Methodology: Appropriate Antipsychotic Use on an Inpatient Dementia Unit Organization: Sheppard Pratt Health System Solution Title: Lean Methodology: Appropriate Antipsychotic Use on an Inpatient Dementia Unit Problem: For dementia patients, antipsychotic medications are prescribed

More information

Screening and Management of Behavioral and Psychiatric Symptoms Associated with Dementia

Screening and Management of Behavioral and Psychiatric Symptoms Associated with Dementia Screening and Management of Behavioral and Psychiatric Symptoms Associated with Dementia Measure Description Percentage of patients with dementia for whom there was a documented screening* for behavioral

More information

The place for treatments of associated neuropsychiatric and other symptoms

The place for treatments of associated neuropsychiatric and other symptoms The place for treatments of associated neuropsychiatric and other symptoms Luca Pani dg@aifa.gov.it London, 25 th November 2014 Workshop on Alzheimer s Disease European Medicines Agency London, UK Public

More information

GERIATRIC MENTAL HEALTH AND MEDICATION TREATMENT

GERIATRIC MENTAL HEALTH AND MEDICATION TREATMENT Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences GERIATRIC MENTAL HEALTH AND MEDICATION TREATMENT RUTH KOHEN ASSOCIATE PROFESSOR UW DEPARTMENT OF PSYCHIATRY 5-4-2017

More information

Psychotropic Medication Use in Dementia

Psychotropic Medication Use in Dementia Psychotropic Medication Use in Dementia Marie A DeWitt, MD Diplomate of the American Board of Psychiatry and Neurology, Specialization in Psychiatry & Subspecialization in Geriatric Psychiatry Staff Physician,

More information

Drugs used to relieve behavioural and psychological symptoms in dementia

Drugs used to relieve behavioural and psychological symptoms in dementia alzheimers.org.uk Drugs used to relieve behavioural and psychological symptoms in dementia People with dementia may develop behavioural and psychological symptoms including restlessness, aggression, delusions,

More information

Managing agitation in dementia using non-pharmacological therapies

Managing agitation in dementia using non-pharmacological therapies Managing agitation in dementia using non-pharmacological therapies Gill Livingston Lynsey Kelly, Elanor Lewis-Holmes, Gianluca Baio, Rumana Omar, Stephen Morris, Nishma Patel, Cornelius Katona, Claudia

More information

Presented by Rengena Chan-Ting, DO, CMD, FACOI Jenna D. Toniatti, PharmD

Presented by Rengena Chan-Ting, DO, CMD, FACOI Jenna D. Toniatti, PharmD Presented by Rengena Chan-Ting, DO, CMD, FACOI Jenna D. Toniatti, PharmD Define BPSD and review the spectrum of associated symptoms Review pharmacologic and non-pharmacologic treatments for BPSD Evaluate

More information

Cognitive enhancers PINCH ME. Anticholinergic burden BPSD. Agitation, Aggression and antipsychotics

Cognitive enhancers PINCH ME. Anticholinergic burden BPSD. Agitation, Aggression and antipsychotics Cognitive enhancers PINCH ME Anticholinergic burden BPSD Agitation, Aggression and antipsychotics 2 types Cholinesterase inhibitors licensed for mild to moderate AD Donepezil Galantamine Rivastigmine also

More information

Management of Behavioral Symptoms in Dementia. Brenda Jordan, MS, ARNP, BC- PCM Dartmouth-Hitchcock Kendal

Management of Behavioral Symptoms in Dementia. Brenda Jordan, MS, ARNP, BC- PCM Dartmouth-Hitchcock Kendal Management of Behavioral Symptoms in Dementia Brenda Jordan, MS, ARNP, BC- PCM Dartmouth-Hitchcock Kendal Behavioral Symptoms Common & troubling At least one will occur in 61-92% of those with any dementia

More information

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process Quality ID #283: Dementia Associated Behavioral and Psychiatric Symptoms Screening and Management National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY

More information

Antipsychotic Medications in the Treatment of Dementia with Behavior Disturbance

Antipsychotic Medications in the Treatment of Dementia with Behavior Disturbance Antipsychotic Medications in the Treatment of Dementia with Behavior Disturbance American Association for Geriatric Psychiatry Los Angeles, CA March 2013 Maureen C. Nash, MD, MS, FAPA Medical Director,

More information

Medications for Anxiety & Behavior in Williams Syndrome. Disclosure of Potential Conflicts. None 9/22/2016. Evaluation

Medications for Anxiety & Behavior in Williams Syndrome. Disclosure of Potential Conflicts. None 9/22/2016. Evaluation Medications for Anxiety & Behavior in Williams Syndrome Christopher J. McDougle, M.D. Director, Lurie Center for Autism Professor of Psychiatry and Pediatrics Massachusetts General Hospital and MassGeneral

More information

Behavioural Problems and Patterns of Psychopharmacological Treatment given in Elderly Patients with Dementia

Behavioural Problems and Patterns of Psychopharmacological Treatment given in Elderly Patients with Dementia The International Journal of Indian Psychology ISSN 2348-5396 (e) ISSN: 2349-3429 (p) Volume 6, Issue 4, DIP: 18.01.090/20180604 DOI: 10.25215/0604.090 http://www.ijip.in October-December, 2018 Research

More information

Behavioural and Psychological Symptoms of Dementia (BPSD) in Primary Care

Behavioural and Psychological Symptoms of Dementia (BPSD) in Primary Care Behavioural and Psychological Symptoms of Dementia (BPSD) in Primary Care Dr. John Puxty Ontario s Ontario s Strategy Strategy for Alzheimer for Disease and Related Dementia: Initiative #2, #2, Physician

More information

From Neurodevelopment to Neurodegeneration: Behavioral Issues

From Neurodevelopment to Neurodegeneration: Behavioral Issues From Neurodevelopment to Neurodegeneration: Behavioral Issues Amer M. Burhan, MBChB, FRCPC Associate Professor and Chair Geriatric Psychiatry at Western U Objectives Discuss factors that contribute to

More information

Psychiatric Morbidity in Dementia Patients in a Neurology-Based Memory Clinic

Psychiatric Morbidity in Dementia Patients in a Neurology-Based Memory Clinic Original Articles 179 Psychiatric Morbidity in Dementia Patients in a Neurology-Based Memory Clinic Ching-Sen Shih 1, Sui-Hing Yan 2, Ying-Hoo Ho 1, Yuh-Te Lin 1, Jie-Yuan Li 1, and Yuk-Keung Lo 1 Abstract-

More information

Pharmacotherapy of Dementia Behaviors

Pharmacotherapy of Dementia Behaviors This Clinical Resource gives subscribers additional insight related to the Recommendations published in June 2017 ~ Resource #330601 Pharmacotherapy of Dementia Behaviors (Also see our chart specific to

More information

Antipsychotics for Dementia Under Control or Over-Prescribed?

Antipsychotics for Dementia Under Control or Over-Prescribed? Antipsychotics for Dementia Under Control or Over-Prescribed? Nathaniel Hedrick, PharmD ProCare HospiceCare, Manager of Clinical Services Learning Objectives Summarize the disease progression and most

More information

40% of mild cognitive impairment 60% of patients in early stage of dementia

40% of mild cognitive impairment 60% of patients in early stage of dementia BPSD Vague and under-researched although described clearly by Alois Alzheimer Term ratified by 1996 IPA consensus conference Not fully recognised in current diagnostic systems Bypassed by dementia strategy

More information

DEMENTIA AND MEDICATION

DEMENTIA AND MEDICATION DEMENTIA AND MEDICATION Dr. Siobhan Ni Bhriain, MRCP, MRCPsych. Clinical Director, Tallaght and SJH MHS, Consultant Old Age Psychiatrist, Chair, DSIDC Steering Committee. SUMMARY OF TODAY S TALK Dementia-definition,

More information

Depression in Late Life

Depression in Late Life Depression in Late Life Robert Madan MD FRCPC Geriatric Psychiatrist Key Learnings Robert Madan MD FRCPC Key Learnings By the end of the session, participants will be able to List the symptoms of depression

More information

Neurocognitive Disorders Research to Emerging Therapies

Neurocognitive Disorders Research to Emerging Therapies Neurocognitive Disorders Research to Emerging Therapies Edward Huey, MD Assistant Professor of Psychiatry and Neurology The Taub Institute for Research on Alzheimer s Disease and the Aging Brain Columbia

More information

Restrained use of antipsychotic medications:

Restrained use of antipsychotic medications: Balanced information for better care Restrained use of antipsychotic medications: Rational management of irrationality These drugs are commonly prescribed in conditions for which there is little evidence

More information

Psychotropic Strategies Handout Package

Psychotropic Strategies Handout Package Psychotropic Strategies Handout Package Psychotropic Strategies Learning Objectives Utilize all clinical information available Assess the patient s overall condition this is essential Basic Principles

More information

9/11/2012. Clare I. Hays, MD, CMD

9/11/2012. Clare I. Hays, MD, CMD Clare I. Hays, MD, CMD Review regulatory background for current CMS emphasis on antipsychotics Understand the risks and (limited) benefits of antipsychotic medications Review non-pharmacologic management

More information

Piecing the Puzzle Together: Pharmacologic Approaches to Behavioral Management in Autism Spectrum Disorder

Piecing the Puzzle Together: Pharmacologic Approaches to Behavioral Management in Autism Spectrum Disorder Piecing the Puzzle Together: Pharmacologic Approaches to Behavioral Management in Autism Spectrum Disorder Hannah Sauer, PharmD PGY1 Pediatric Pharmacy Resident Mayo Clinic 2015 MFMER slide-1 Objectives

More information

Evaluation and Management of Agitation and Aggression in Dementia Joseph W. Shega, MD National Medical Director

Evaluation and Management of Agitation and Aggression in Dementia Joseph W. Shega, MD National Medical Director Evaluation and Management of Agitation and Aggression in Dementia Joseph W. Shega, MD National Medical Director Objectives Differentiate between delirium, terminal restlessness, and dementia related agitation

More information

Dementia ALI ABBAS ASGHAR-ALI, MD STAFF PSYCHIATRIST MICHAEL E. DEBAKEY VA MEDICAL CENTER ASSOCIATE PROFESSOR BAYLOR COLLEGE OF MEDICINE

Dementia ALI ABBAS ASGHAR-ALI, MD STAFF PSYCHIATRIST MICHAEL E. DEBAKEY VA MEDICAL CENTER ASSOCIATE PROFESSOR BAYLOR COLLEGE OF MEDICINE Dementia ALI ABBAS ASGHAR-ALI, MD STAFF PSYCHIATRIST MICHAEL E. DEBAKEY VA MEDICAL CENTER ASSOCIATE PROFESSOR BAYLOR COLLEGE OF MEDICINE Objectives At the conclusion of the session, participants will be

More information

Addressing Difficult Behaviors in Dementia

Addressing Difficult Behaviors in Dementia Addressing Difficult Behaviors in Dementia GEORGE SCHOEPHOERSTER, MD GERIATRICIAN GENEVIVE/CENTRACARE CLINIC Objectives By the end of the session, you will be able to: 1) Explain the role of pain management

More information

A Basic Approach to Mood and Anxiety Disorders in the Elderly

A Basic Approach to Mood and Anxiety Disorders in the Elderly A Basic Approach to Mood and Anxiety Disorders in the Elderly November 1 2013 Sarah Colman MD FRCPC Clinical Fellow, Geriatric Psychiatry Mount Sinai Hospital, University of Toronto Disclosure No conflict

More information

Parkinsonian Disorders with Dementia

Parkinsonian Disorders with Dementia Parkinsonian Disorders with Dementia George Tadros Consultant in Old Age Liaison Psychiatry, RAID, Heartlands Hospital Professor of Dementia and Liaison Psychiatry, Aston Medical School Aston University

More information

Management of the behavioral and psychological symptoms of dementia

Management of the behavioral and psychological symptoms of dementia REVIEW Management of the behavioral and psychological symptoms of dementia Elizabeth C Hersch Sharon Falzgraf VA Puget Sound Health Care System, Tacoma, Washington, USA Correspondence: Elizabeth C Hersch

More information

Debra Brown, PharmD, FASCP Pharmaceutical Consultant II Specialist. HMS Training Webinar January 27, 2017

Debra Brown, PharmD, FASCP Pharmaceutical Consultant II Specialist. HMS Training Webinar January 27, 2017 Debra Brown, PharmD, FASCP Pharmaceutical Consultant II Specialist HMS Training Webinar January 27, 2017 1 Describe nationwide prevalence and types of elderly dementia + define BPSD Define psychotropic

More information

Pregnancy. General Principles of Prescribing in Pregnancy (The Maudsley, 12 th Edition)

Pregnancy. General Principles of Prescribing in Pregnancy (The Maudsley, 12 th Edition) Pregnancy General Principles of Prescribing in Pregnancy (The Maudsley, 12 th Edition) In all women of child bearing potential Always discuss the possibility of pregnancy; half of all pregnancies are unplanned

More information

Assessment and management of behavioral. B ehavior al and psychological symptoms of dementia are STATE OF THE ART REVIEW

Assessment and management of behavioral. B ehavior al and psychological symptoms of dementia are STATE OF THE ART REVIEW Assessment and management of behavioral and psychological symptoms of dementia Helen C Kales, 1 2 3 Laura N Gitlin, 4 5 6 Constantine G Lyketsos 7 1 Section of Geriatric Psychiatry, Department of Psychiatry,

More information

Psychotropic Medication. Including Role of Gradual Dose Reductions

Psychotropic Medication. Including Role of Gradual Dose Reductions Psychotropic Medication Including Role of Gradual Dose Reductions What are they? The phrase psychotropic drugs is a technical term for psychiatric medicines that alter chemical levels in the brain which

More information

10/5/2017. BEHAVIORAL and PSYCHOLOGICAL SYMPTOMS in DEMENTIA (BPSD) Dr. Shah MD, MPH Braodlawns Medical Center DISCLOSURE

10/5/2017. BEHAVIORAL and PSYCHOLOGICAL SYMPTOMS in DEMENTIA (BPSD) Dr. Shah MD, MPH Braodlawns Medical Center DISCLOSURE 1 BEHAVIORAL and PSYCHOLOGICAL SYMPTOMS in DEMENTIA (BPSD) Dr. Shah MD, MPH Braodlawns Medical Center DISCLOSURE 2 Dr. Shah has no relevant conflicts with commercial interests to disclose. OBJECTIVES 3

More information

Dementia and Fall Geriatric Interprofessional Training. Wael Hamade, MD, FAAFP

Dementia and Fall Geriatric Interprofessional Training. Wael Hamade, MD, FAAFP Dementia and Fall Geriatric Interprofessional Training Wael Hamade, MD, FAAFP Prevalence of Dementia Age range 65-74 5% % affected 75-84 15-25% 85 and older 36-50% 5.4 Million American have AD Dementia

More information

Pharmacological Management of Dementia-Related Behaviors

Pharmacological Management of Dementia-Related Behaviors Welcomes You To Pharmacological Management of Dementia-Related Behaviors Presented by Brett Lu, MD, PhD Associate Professor of Psychiatry John A. Burns School of Medicine September 5, 2017 10:00 11:00

More information

2/9/2018. Certificate of Completion: Pharmacological Management of Dementia Related Behaviors. Welcomes You To

2/9/2018. Certificate of Completion: Pharmacological Management of Dementia Related Behaviors. Welcomes You To Welcomes You To Pharmacological Management of Dementia Related Behaviors Presented by Brett Lu, MD, PhD Associate Professor of Psychiatry John A. Burns School of Medicine September 5, 2017 10:00 11:00

More information

Antipsychotic use in dementia: a systematic review of benefits and risks from metaanalyses

Antipsychotic use in dementia: a systematic review of benefits and risks from metaanalyses 658463TAJ0010.1177/2040622316658463Therapeutic Advances in Chronic DiseaseRR Tampi, DJ Tampi research-article2016 Therapeutic Advances in Chronic Disease Original Research Antipsychotic use in dementia:

More information

November 16-18, 2017 Hotel Monteleone New Orleans, LA. Provided by

November 16-18, 2017 Hotel Monteleone New Orleans, LA. Provided by November 16-18, 2017 Hotel Monteleone New Orleans, LA Provided by Major Neurocognitive Disorder: The Beginning and the End. Making the Diagnosis and Addressing Distressing Behavior W. Vaughn McCall, MD,

More information

The efficacy of Rivastigmine in the management of the behavioral and psychological symptoms of lewy body dementia- a review of literature

The efficacy of Rivastigmine in the management of the behavioral and psychological symptoms of lewy body dementia- a review of literature Review article: The efficacy of Rivastigmine in the management of the behavioral and psychological symptoms of lewy body dementia- a review of literature Dr. Ivan Netto 1, Aditya Iyer 2, Dr. Prathamesh

More information

Opinion statement. Introduction. Cognitive Disorders (M Geschwind, Section Editor)

Opinion statement. Introduction. Cognitive Disorders (M Geschwind, Section Editor) Current Treatment Options in Neurology DOI 10.1007/s11940-012-0166-9 Cognitive Disorders (M Geschwind, Section Editor) Treatment of Behavioral and Psychological Symptoms of Alzheimer s Disease Anne Corbett,

More information

Dementia: Managing Difficult Behaviors. No conflicts of interest. Off-label medication use will be discussed during this talk.

Dementia: Managing Difficult Behaviors. No conflicts of interest. Off-label medication use will be discussed during this talk. Dementia: Managing Difficult Behaviors No conflicts of interest. Off-label medication use will be discussed during this talk. 1 Types of Neurocognitive Disorder Alzheimer s Disease Vascular Frontotemporal

More information

Diagnosis and Treatment of Alzhiemer s Disease

Diagnosis and Treatment of Alzhiemer s Disease Diagnosis and Treatment of Alzhiemer s Disease Roy Yaari, MD, MAS Director, Memory Disorders Clinic, Banner Alzheimer s Institute 602-839-6900 Outline Introduction Alzheimer s disease (AD)Guidelines -revised

More information

Medications and Non-Pharma Approaches to Treatment. David J. Irwin, MD Penn Frontotemporal Degeneration Center

Medications and Non-Pharma Approaches to Treatment. David J. Irwin, MD Penn Frontotemporal Degeneration Center Medications and Non-Pharma Approaches to Treatment David J. Irwin, MD Penn Frontotemporal Degeneration Center Outline Non-Pharmacological Treatment Strategies Behavior Language Motor Supportive Care Check-points

More information

11/11/2016. Relevant Disclosures Current or past. Outline

11/11/2016. Relevant Disclosures Current or past. Outline Management of Agitation in Dementia 2016 Update Constantine G. Lyketsos, MD, MHS Interim Chair of Psychiatry, Johns Hopkins Medicine Elizabeth Plank Althouse Professor, Johns Hopkins University kostas@jhmi.edu

More information

Neuropsychiatric Manifestations in Vascular Cognitive Impairment Patients with and without Dementia

Neuropsychiatric Manifestations in Vascular Cognitive Impairment Patients with and without Dementia 86 Neuropsychiatric Manifestations in Vascular Cognitive Impairment Patients with and without Dementia Pai-Yi Chiu 1,3, Chung-Hsiang Liu 2, and Chon-Haw Tsai 2 Abstract- Background: Neuropsychiatric profile

More information

Background. Population/Intervention(s)/Comparison/Outcome(s) (PICO) Role of antidepressants in people with dementia and associated depression

Background. Population/Intervention(s)/Comparison/Outcome(s) (PICO) Role of antidepressants in people with dementia and associated depression updated 2012 Role of antidepressants in people with dementia and associated depression Q4: For people with dementia with associated depression, do antidepressants when compared to placebo/comparator produce

More information

Cognitive disorders. Dr S. Mashaphu Department of Psychiatry

Cognitive disorders. Dr S. Mashaphu Department of Psychiatry Cognitive disorders Dr S. Mashaphu Department of Psychiatry Delirium Syndrome characterised by: Disturbance of consciousness Impaired attention Change in cognition Develops over hours-days Fluctuates during

More information

PDFlib PLOP: PDF Linearization, Optimization, Protection. Page inserted by evaluation version

PDFlib PLOP: PDF Linearization, Optimization, Protection. Page inserted by evaluation version PDFlib PLOP: PDF Linearization, Optimization, Protection Page inserted by evaluation version www.pdflib.com sales@pdflib.com doi:10.1111/j.1479-8301.2007.00215.x PSYCHOGERIATRICS 2008; 8: 32 37 REVIEW

More information

Psychopharmacology in the Emergency Room. Michael D. Jibson, M.D., Ph.D. Associate Professor of Psychiatry University of Michigan

Psychopharmacology in the Emergency Room. Michael D. Jibson, M.D., Ph.D. Associate Professor of Psychiatry University of Michigan Psychopharmacology in the Emergency Room Michael D. Jibson, M.D., Ph.D. Associate Professor of Psychiatry University of Michigan Pretest 1. Appropriate target symptoms for emergency room medication treatment

More information

Reducing the Anxiety of Pediatric Anxiety Part 2: Treatment

Reducing the Anxiety of Pediatric Anxiety Part 2: Treatment Reducing the Anxiety of Pediatric Anxiety Part 2: Treatment Lisa Lloyd Giles, MD Medical Director, Behavioral Consultation, Crisis, and Community Services Primary Children s Hospital Associate Professor,

More information

Antidepressants. Dr Malek Zihlif

Antidepressants. Dr Malek Zihlif Antidepressants The optimal use of antidepressant required a clear understanding of their mechanism of action, pharmacokinetics, potential drug interaction and the deferential diagnosis of psychiatric

More information

9/24/2012. Amer M Burhan, MBChB, FRCP(C)

9/24/2012. Amer M Burhan, MBChB, FRCP(C) Depression and Dementia Amer M Burhan MBChB, FRCPC Head of CAMH Memory Clinic, Toronto Geriatric Neuropsychiatrist Assistant Prof Psychiatry at U of T Objectives Discuss the prevalence and impact of depression

More information

Pharmacologic Management of Mood and Behavioral Changes in

Pharmacologic Management of Mood and Behavioral Changes in Pharmacologic Management of Mood and Behavioral Changes in Dementia James E. Galvin, MD, MPH Professor of Neurology and Psychiatry New York University Langone Medical Center CADASIL MRI scan showing leukoencephalopathyon

More information

Introduction to Drug Treatment

Introduction to Drug Treatment Introduction to Drug Treatment LPT Gondar Mental Health Group www.le.ac.uk Introduction to Psychiatric Drugs Drugs and Neurotransmitters 5 Classes of Psychotropic medications Mechanism of action Clinical

More information

An Evaluation of a Training Program in Restraint-Free Care for Individuals with Dementia Christina Garrison-Diehn, Clair Rummel, & Jane E.

An Evaluation of a Training Program in Restraint-Free Care for Individuals with Dementia Christina Garrison-Diehn, Clair Rummel, & Jane E. An Evaluation of a Training Program in Restraint-Free Care for Individuals with Dementia Christina Garrison-Diehn, Clair Rummel, & Jane E. Fisher Background Disease. (Xu, Kochanek & Tejada-Vera, 2009)

More information

Mood Disorders.

Mood Disorders. Mood Disorders Shamim Nejad, MD Medical Director, Psycho-Oncology Services Swedish Cancer Institute Swedish Medical Center Seattle, Washington Shamim.Nejad@swedish.org Disclosures Neither I nor my spouse/partner

More information

Alison Charleston 1 st September 2016

Alison Charleston 1 st September 2016 Alison Charleston 1 st September 2016 Clinical features of Parkinson s disease Differential diagnosis Management of the motor features Non-motor and neuropsychiatric aspects 100-200 per 100,000 prevalence

More information

Assessing and Treating Agitation Associated with Alzheimer s Disease

Assessing and Treating Agitation Associated with Alzheimer s Disease AXS-05 R&D Day April 24, 2018 Assessing and Treating Agitation Associated with Alzheimer s Disease Marc E. Agronin, MD VP, Behavioral Health and Clinical Research, Miami Jewish Health Affiliate Associate

More information

Augmentation and Combination Strategies in Antidepressants treatment of Depression

Augmentation and Combination Strategies in Antidepressants treatment of Depression Augmentation and Combination Strategies in Antidepressants treatment of Depression Byung-Joo Ham, M.D. Department of Psychiatry Korea University College of Medicine Background The response rates reported

More information

Management of agitation and aggression associated with Alzheimer disease

Management of agitation and aggression associated with Alzheimer disease Management of agitation and aggression associated with Alzheimer disease Clive G. Ballard, Serge Gauthier, Jeffrey L. Cummings, Henry Brodaty, George T. Grossberg, Philippe Robert and Constantine G. Lyketsos

More information

Delirium. Approach. Symptom Update Masterclass:

Delirium. Approach. Symptom Update Masterclass: Symptom Update Masterclass: Delirium Jason Boland Senior Clinical Lecturer and Honorary Consultant in Palliative Medicine Wolfson Centre for Palliative Care Research Hull York Medical School University

More information

Behavioral Management in Dementia. a.k.a. Public Enemy Number One a.k.a. Proteins Gone Bad

Behavioral Management in Dementia. a.k.a. Public Enemy Number One a.k.a. Proteins Gone Bad Behavioral Management in Dementia a.k.a. Public Enemy Number One a.k.a. Proteins Gone Bad Game Plan 1. Definition 2. Epidemiology 3. Assessment: IT S OVER 4. Nonpharmacologic Strategies: 4 S 5. Nonpharmacologic:

More information

Pharmacologyonline 1: (2009) ewsletter Rosanna Erra. Atypical Antipsychotic Drugs for the Treatment of BPSD. in Subjects with Dementia

Pharmacologyonline 1: (2009) ewsletter Rosanna Erra. Atypical Antipsychotic Drugs for the Treatment of BPSD. in Subjects with Dementia Atypical Antipsychotic Drugs for the Treatment of BPSD in Subjects with Dementia Rosanna Erra School of Pharmacy, University of Salerno, Italy ros.erra@libero.it Summary Behavioural and psychological disorders

More information

Any interventions, where RCTs in PD are not available, are not included in the tables.

Any interventions, where RCTs in PD are not available, are not included in the tables. Tables Interventions where new studies have been published are indicated in bold italics. Changes in conclusions are indicated in italics and are highlighted in yellow. Any interventions, where RCTs in

More information

Responsiveness of the QUALID to Improved Neuropsychiatric Symptoms in Patients with Alzheimer s Disease

Responsiveness of the QUALID to Improved Neuropsychiatric Symptoms in Patients with Alzheimer s Disease ORIGINAL RESEARCH Responsiveness of the QUALID to Improved Neuropsychiatric Symptoms in Patients with Alzheimer s Disease Hadas Benhabib 1, Krista L. Lanctôt, PhD 1,2,4, Goran M. Eryavec, MD, FRCPC 3,4,

More information

Reality, as perceived by the patient, constitutes the reality of the situation. My Mother s Doing What???!!

Reality, as perceived by the patient, constitutes the reality of the situation. My Mother s Doing What???!! My Mother s Doing What???!! Management & Treatment of Dementia Related Behaviors Objectives Describe the prevalence, etiology of dementia related behaviors that include physical outbursts & sexual hyperactivity.

More information